Scarica l'app Stockscreener
0.332
17.21%
-0.069
Dopo l'orario di chiusura:
.34
0.008
+2.41%
Precedente Chiudi:
$0.401
Aprire:
$0.38
Volume 24 ore:
686.19K
Relative Volume:
2.22
Capitalizzazione di mercato:
$12.54M
Reddito:
-
Utile/perdita netta:
$-10.21M
Rapporto P/E:
-0.5683
EPS:
-0.5842
Flusso di cassa netto:
-
1 W Prestazione:
-17.33%
1M Prestazione:
-31.43%
6M Prestazione:
-61.76%
1 anno Prestazione:
-75.59%
Intervallo 1D:
$0.332
$0.3868
Intervallo di 1 settimana:
$0.332
$0.5257
Portata 52W:
$0.25
$1.3319
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Nome
Neurosense Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Compare NRSN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.332 | 15.14M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurosense Therapeutics Ltd Borsa (NRSN) Ultime notizie
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - TipRanks
12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com
NeuroSense (NASDAQ: NRSN) cuts share count to 1.9M in 1-for-20 split - Stock Titan
Why Is NeuroSense (NASDAQ:NRSN) in Focus Before Tuesday’s Open? - Kalkine Media
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
Amyotrophic Lateral Sclerosis Pipeline 2026: FDA Approvals, - openPR.com
NRSN Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS - Morningstar
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - TipRanks
NeuroSense (NRSN) gains 12‑month mandate for reverse share split - Stock Titan
NeuroSense Therapeutics Ltd. Warrant (NRSNW) Peer Comparison – Compare with Others - valueresearchonline.com
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN - TradingView
12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - vinanet.vn
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail
Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com
NeuroSense Issues CEO Letter to Shareholders - Nasdaq
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et
Global Neurodegenerative Disease Market is Expected to - GlobeNewswire
NeuroSense Therapeutics (NRSN) Dips 1.6% to $0.49, Testing Key Support at $0.47PCR Moving Average - dars.gov.et
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - GuruFocus
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan
NeuroSense Therapeutics (NRSN) Jumps 11.35% to $0.52, Nears Key Resistance at $0.55Weekly Profile - dars.gov.et
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
NeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock Titan
NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split - TipRanks
NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push - Stock Titan
NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective - TipRanks
NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan - Stock Titan
NeuroSense Therapeutics (NRSN) Plunges 14% – Testing Critical Support at $0.46Sentiment Shift - vinanet.vn
Neurosense Therapeutics is a buy, this analyst says - Cantech Letter
Neurosense Therapeutics Ltd expected to post breakeven results a shareEarnings Preview - TradingView
Neurosense Therapeutics Ltd. Revenue Breakdown – FWB:H1Z - TradingView
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSN) Cash Flow - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048 - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.511|Chg%:+0.109 - TradingKey
TradingKey - TradingKey
NeuroSense Therapeutics (NRSN) Gains 3.08% as Stock Tests Key Resistance at $0.70Upthrust Pattern - vinanet.vn
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS - TipRanks
NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug - Stock Titan
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PR Newswire
NRSN Q2 2025 Earnings: Narrower-than-Expected Loss Fails to Soothe ShareholdersHealthcare Earnings Report - vinanet.vn
NeuroSense Therapeutics (NRSN) Faces Headwinds: Stock Retreats 5.6% to $0.69 Amid Sector PressureMarket Profile - vinanet.vn
NeuroSense Therapeutics (NRSN) Slips 2.6% as Stock Tests Key Support at $0.65Cumulative Volume - vinanet.vn
NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66Calendar Spread Trade - dars.gov.et
NeuroSense Therapeutics (NRSN) Edges Higher as Key Support HoldsEquity Put Call - dars.gov.et
Neurosense Therapeutics Ltd Azioni (NRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):